Quantcast
Channel: Xconomyvaccines – Xconomy
Browsing latest articles
Browse All 111 View Live

Image may be NSFW.
Clik here to view.

Neon’s Early Vaccine Study Is a Peek at Immunotherapy’s Third Wave

In this new age of cancer immunotherapy, two versions have been approved. The first are checkpoint inhibitors, which have begun to change the way skin, lung, and other cancers are treated. The second...

View Article



Image may be NSFW.
Clik here to view.

Elanco Boosts Vaccine Portfolio With $60M Prevtec Acquisition

One of the most serious threats to a young farm pig’s life is a type of gut infection that can quickly turn deadly. Elanco Animal Health has acquired a Canadian biotechnology startup that has...

View Article

Image may be NSFW.
Clik here to view.

Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus

No vaccine is yet available for respiratory syncytial virus (RSV), which causes lung infections that, while usually mild, can be deadly for very young children. Biotech startup Meissa Vaccines, which...

View Article

Image may be NSFW.
Clik here to view.

Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More

Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the...

View Article

Image may be NSFW.
Clik here to view.

Icosavax Lands $51M to Bring Vaccine for Respiratory Virus to Clinic

Many vaccines are made from either a weakened virus or a protein taken from a virus. But so far, scientists haven’t had much luck developing such vaccines for respiratory syncytial virus (RSV), which...

View Article


Image may be NSFW.
Clik here to view.

Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff

Merck is corralling products representing $6.5 billion in sales and spinning them off into a separate company, a strategic bet that focusing the remaining business on developing innovative new...

View Article

Image may be NSFW.
Clik here to view.

Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible.Fallout from the spread of COVID-19 infections led several companies to...

View Article

Image may be NSFW.
Clik here to view.

Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance

Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that...

View Article


Image may be NSFW.
Clik here to view.

GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months

GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental...

View Article


Image may be NSFW.
Clik here to view.

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in healthy volunteers.The Plymouth Meeting, PA-based...

View Article

Image may be NSFW.
Clik here to view.

Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month

Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks.The partnership...

View Article

Image may be NSFW.
Clik here to view.

GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year

[Updated, 3:13 p.m. See below.] Pharmaceutical giants GlaxoSmithKline and Sanofi are teaming up on COVID-19 research, aiming to combine their respective technologies in a new vaccine that could start...

View Article

Image may be NSFW.
Clik here to view.

Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory

Affinivax has a lead program with early clinical data showing the potential to best a pharmaceutical giant’s blockbuster vaccine. The startup now has $120 million in financing to see just how much...

View Article


Image may be NSFW.
Clik here to view.

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to...

View Article

Image may be NSFW.
Clik here to view.

Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More

As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything...

View Article


Image may be NSFW.
Clik here to view.

Fauci Foresees “More Than 1 Winner” in Race for COVID-19 Vaccines, Drugs

To ameliorate a pandemic that infectious disease expert Anthony Fauci calls his “worst nightmare,” a winner-takes-all solution won’t be enough.Fauci, who directs the National Institute of Allergy and...

View Article

Image may be NSFW.
Clik here to view.

Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine

Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test.The study, set to begin next...

View Article


Image may be NSFW.
Clik here to view.

Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More

The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire...

View Article

Image may be NSFW.
Clik here to view.

Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test

Pfizer and BioNTech’s COVID-19 vaccine research started with multiple approaches—four shots on the messenger RNA goal. The partners have narrowed their choices to one for pivotal testing, and that...

View Article

Image may be NSFW.
Clik here to view.

Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political

Pfizer Inc. CEO Albert Bourla said he doesn’t worry about political pressure to bring potentially the first coronavirus vaccine to market, but can’t escape feeling the weight of the world on his...

View Article
Browsing latest articles
Browse All 111 View Live




Latest Images